The one question that decides your pathway

The answer to 'Is ChondroFiller right for me?' rests on a single clinical distinction — not how severe your pain is, not your age, and not how long you have been symptomatic. It rests on whether the cartilage damage is confined to a defined area of the joint, or whether it has spread across multiple surfaces.

When damage is localised — a discrete Grade III or IV chondral lesion, up to around 6 cm², sitting within a joint that is otherwise structurally sound — ChondroFiller is designed precisely for that situation. The scaffold fills the defect and recruits the body's own progenitor cells to begin the repair process from within. The surrounding cartilage acts as a healthy border; the joint itself retains its architecture.

When the picture is different — when degeneration has spread across two or more compartments, leaving no intact border cartilage and no contained defect to fill — the treatment goal changes entirely. Structural restoration of a defined hole is no longer possible, and a different clinical pathway applies. This is why two patients presenting with similar knee pain and similar disability can be suitable for quite different interventions.

How ChondroFiller works as an injectable scaffold

Placed into the defect via an ultrasound-guided outpatient injection, ChondroFiller is a CE-marked Class III acellular Type I collagen hydrogel — two components that remain liquid in the syringe and polymerise into a stable three-dimensional matrix within three to five minutes of reaching the joint. No cells are injected; the scaffold itself does the recruiting.

Once set, the matrix draws the patient's own progenitor cells inward from two local sources: the synovium lining the joint capsule and the subchondral bone beneath the defect floor. This is acellular matrix-induced chondrogenesis — the injected material promotes endogenous repair by providing the structural environment cells need to migrate, adhere, and differentiate, rather than delivering them from an outside source. An ex vivo study using standardised four-millimetre full-thickness defects in 61 osteochondral explants found a 2.4-fold increase in DNA content within the ChondroFiller group by day 14, confirming that cellular infiltration into the scaffold proceeds rapidly at a tissue level.

The repair logic is additive and directional: the gel fills the defect base and builds upward toward the cartilage surface, integrating with the intact border cartilage on each side. That process depends on geometry — a defined floor, walls of healthy tissue, and subchondral bone close enough to supply the migratory cell pool. Precisely which joints and lesion profiles meet those geometric requirements is what patient selection criteria address.

What the right candidate actually looks like

Three clinical factors, taken together, determine whether ChondroFiller is the right pathway: the lesion itself, the tissue surrounding it, and the broader state of the joint.

The lesion profile. Suitable candidates typically present with an isolated ICRS or Outerbridge Grade III or IV chondral defect — deep enough to impair function, but contained within a measurable footprint of up to approximately 6 cm². Critically, the cartilage at the defect margin must be intact: that healthy border provides the structural wall the in-situ scaffold needs to build against.

The joint environment. ChondroFiller requires a joint that retains its fundamental architecture. Significant ligamentous instability, major mechanical malalignment, or multi-compartment cartilage degeneration each remove the structural conditions the repair process depends on. Active inflammatory joint disease is a separate contraindication.

What MRI confirms

When imaging identifies a focal defect with healthy surrounding cartilage and a sound joint overall, the ultrasound-guided injection pathway can proceed without arthroscopic staging — MRI replaces the surgical assessment step. Single-compartment disease with one dominant focal lesion may still qualify if adjacent compartments remain intact, though this requires individual MRI review rather than a blanket rule; published guidance on this overlap zone remains limited.

Clear exclusion signals include Kellgren–Lawrence Grade III or IV osteoarthritis spread across more than one compartment, an absent or degraded defect border, and subchondral bone pathology extending beyond the lesion itself.

Clinical outcomes in focal defect patients

For patients who meet those criteria, the published functional data are encouraging. In a knee cohort of 17 patients (mean age 31) followed over a study period spanning 2012 to 2023, Lysholm and IKDC scores improved significantly at 3, 6, and 12 months post-treatment (p<0.05), with mean IKDC gains of approximately 30 points — a threshold the field treats as clinically meaningful, not merely statistical.

The same pattern holds in other joints where ChondroFiller has been formally evaluated. A hip cohort of 26 patients with acetabular lesions greater than 2 cm² achieved a mean Harris Hip Score improvement of approximately 33 points, with 17 of 21 patients reaching good or excellent ratings at three to five years. MRI-assessed cartilage fill, measured by MOCART score, ranged from 70 to 87 across published series — indicating good-to-very-good structural repair in correctly selected patients.

The hip cohort also provided the clearest published evidence for why selection matters: patients with pre-existing osteoarthritis (Tönnis grade 2–3) had uniformly poor results, and two subsequently required total hip replacement. That finding is not incidental — it is the clinical argument for the MRI-led assessment process described in the preceding section.

Adverse event rates across published data are approximately 0.06%, consistent with a well-tolerated outpatient injection pathway.

The main gap in the evidence base is comparative. Randomised data against microfracture exists, but the trial enrolled only 23 patients and had high dropout in the control arm; that limits how firmly superiority over established surgical alternatives can be claimed. Published outcomes support cautious optimism for appropriately selected candidates, rather than a definitive hierarchy.

When osteoarthritis changes the treatment goal

Diffuse osteoarthritis presents a different clinical problem. Where a focal defect has a defined cavity with intact walls, multi-compartment or end-stage OA involves broad surface loss across a joint that has no comparable healthy border. Rebuilding from the bottom up is structurally impossible when there is no contained space to anchor the scaffold. Used in its focal-defect mode, ChondroFiller is not appropriate in this setting.

The treatment goal shifts accordingly — from structural restoration to surface support and symptom management. Clinically, this distinction has been described as an additive 'top-down' protective coating rather than a fill-and-restore repair. These are not interchangeable objectives, and applying the wrong framework to either pathway produces poor results, as the hip cohort data discussed in the preceding section illustrate.

A dual-component protocol for selected OA patients

For patients with Kellgren–Lawrence Grade III or IV osteoarthritis, a combined in-clinic injection approach has been described in clinical practice: ChondroFiller (2.3 mL, delivered to bone-end surfaces) paired with a polyacrylamide hydrogel cushioning agent (6 mL, placed intra-synovially). In this configuration, ChondroFiller provides local scaffold support while the hydrogel integrates into the synovial membrane to act as a mechanical cushion. Each component serves a distinct biological role; the two should not be treated as a single composite product or conflated into one generic category.

The hydrogel element does not recruit cells or promote tissue repair — it is a non-biodegradable mechanical device. ChondroFiller's acellular matrix-induced chondrogenesis mechanism remains active, but the clinical objective has shifted from defect fill to broad surface support.

The evidence basis for this protocol comes from internal clinical positioning documents rather than published peer-reviewed trials, and independent durability data are not yet available. Where joint degeneration has progressed beyond any preservation pathway, arthroplasty assessment remains the appropriate next step.

Recovery after the injection and realistic expectations

The six-week period of protected weight-bearing that follows the injection is not precautionary convention — it reflects the scaffold's actual biomechanical state. ChondroFiller polymerises in situ, but the early gel matrix cannot withstand joint loading without risk of mechanical disruption; in vitro testing under cyclic loading confirmed that the scaffold, in its initial phase, does not reduce damage to the opposing cartilage surface. Stable integration must precede full load.

Functional improvement follows a gradual trajectory. In the published knee cohort, IKDC scores improved significantly across three, six, and twelve months, with gains stabilising between six and twelve months — suggesting that meaningful benefit accumulates within the first half-year rather than arriving as a sharp post-procedure change. Hip outcomes at three to five years show those improvements are durable rather than transient. Return to high-impact activity typically takes up to twelve months.

The strongest predictor of where that trajectory ends is the clinical decision reached before the appointment: MRI-confirmed defect morphology and surrounding cartilage integrity set the ceiling on what the recovery period can deliver. No rehabilitation programme extends that ceiling.

For patients across London and the south-east, specialist cartilage assessment and ultrasound-guided ChondroFiller injection are available at London Cartilage Clinic on Harley Street.

1. [1] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration Investigation. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Implantation of ChondroFiller Liquid® as scaffold for chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Influence of cartilage defects and collagen gel on integrity of adjacent cartilage: biomechanical in vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z